Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.98 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.98 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | RXRA | P19793 | 1/20 | 0.98 |
| ▸ | CCKAR | P32238 | 1/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL1147657 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6250394 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL4620256 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL1147653 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL41662 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL41664 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL5072556 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL344982 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6270543 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL28166565 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476432-B2 | Process for the preparation of HMG-COA reductase inhibitors and intermediates thereof | YUHAN CORPORATION (KR) | 2013-07-02 | — | — | US | disclosed |
| EP-2588474-A2 | PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF | Yuhan Corporation (KR) | 2013-05-08 | — | — | EP | disclosed |
| US-20130096303-A1 | PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF | YUHAN CORPORATION (KR) | 2013-04-18 | — | — | US | disclosed |
| WO-2012002741-A2 | PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF | YUHAN CORPORATION (KR) | 2012-01-05 | — | — | WO | disclosed |
| US-20100249204-A1 | CALCIUM SALTS OF INDOLE DERIVED STATINS | CHEN GUANG-PEI | 2010-09-30 | — | — | US | disclosed |
| EP-1472228-B1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | NOVARTIS AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| EP-1515717-B1 | CALCIUM SALTS OF INDOLE DERIVED STATINS | NOVARTIS AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-7371865-B2 | Process for the manufacture of HMG-CoA reductase inhibitors | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20060035941-A1 | Calcium salts of indole derived statins | CHEN GUANG-PEI | 2006-02-16 | — | — | US | disclosed |
| US-20050070605-A1 | Process for the manufacture of hmg-coa reductase inhibitors | ACEMOGLU MURAT (CH) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249204-A1 | CALCIUM SALTS OF INDOLE DERIVED STATINS | ORAI1, ACSL3, CACNA1E | HMGCR 11/4885CYP2C9 301/4885SIRT6 1868/4885 |
| US-20050070605-A1 | Process for the manufacture of hmg-coa reductase inhibitors | HMGCR, COASY, DHCR7 | HMGCR 1/4885CYP2C9 155/4885SIRT6 429/4885 |
| US-20060035941-A1 | Calcium salts of indole derived statins | ITPR3, CACNA1E, ORAI1 | HMGCR 11/4885CYP2C9 294/4885SIRT6 2194/4885 |
| US-20130096303-A1 | PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF | HMGCR, COASY, PCSK9 | HMGCR 1/4885CYP2C9 270/4885SIRT6 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.